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Mutations in the GLI3 zinc-finger transcription factor gene cause Greig cephalopolysyndactyly syndrome (GCPS)
and Pallister-Hall syndrome (PHS), which are variable but distinct clinical entities. We hypothesized that GLI3
mutations that predict a truncated functional repressor protein cause PHS and that functional haploinsufficiency
of GLI3 causes GCPS. To test these hypotheses, we screened patients with PHS and GCPS for GLI3 mutations.
The patient group consisted of 135 individuals: 89 patients with GCPS and 46 patients with PHS. We detected 47
pathological mutations (among 60 probands); when these were combined with previously published mutations,
two genotype-phenotype correlations were evident. First, GCPS was caused by many types of alterations, including
translocations, large deletions, exonic deletions and duplications, small in-frame deletions, and missense, frameshift/
nonsense, and splicing mutations. In contrast, PHS was caused only by frameshift/nonsense and splicing mutations.
Second, among the frameshift/nonsense mutations, there was a clear genotype-phenotype correlation. Mutations
in the first third of the gene (from open reading frame [ORF] nucleotides [nt] 1–1997) caused GCPS, and mutations
in the second third of the gene (from ORF nt 1998–3481) caused primarily PHS. Surprisingly, there were 12
mutations in patients with GCPS in the 3′ third of the gene (after ORF nt 3481), and no patients with PHS had
mutations in this region. These results demonstrate a robust correlation of genotype and phenotype for GLI3
mutations and strongly support the hypothesis that these two allelic disorders have distinct modes of pathogenesis.
Introduction
Mutations in the GLI3 zinc-finger transcription factor
on chromosome 7p14.1 cause the Pallister-Hall syn-
drome (PHS [MIM 146510]) (Kang et al. 1997b) and
the Greig cephalopolysyndactyly syndrome (GCPS [MIM
175700]) (Vortkamp et al. 1991), both of which are
inherited in an autosomal dominant pattern. Although
both disorders manifest postaxial polydactyly, PHS and
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GCPS are distinct clinical entities with numerous non-
overlapping features (Biesecker et al. 1996; Gorlin et al.
2001). Clinical features that distinguish the disorders
include hypothalamic hamartoma, bifid epiglottis, and
insertional polydactyly in PHS and preaxial polydactyly
and hypertelorism in GCPS. Three types of apparently
isolated polydactyly—PAP-A, PAP-A/B, and PPD-IV—
are also caused by GLI3 mutations (Radhakrishna et al.
1997, 1999), and a GLI3 mutation was reported in a
child with features of GCPS and acrocallosal syndrome
(Elson et al. 2002). Therefore, the clinical phenotypes
caused by mutations in GLI3 are diverse and complex.
GLI3 acts as both a transcriptional activator and a
transcriptional repressor of downstream targets in the
sonic hedgehog (SHH) pathway during development
(Ruiz i Altaba 1999). In the presence of SHH, full-length
GLI3 up-regulates target genes, whereas, in the absence
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Figure 1 Flow chart showing numbers of patients included in each part of the study. Notice that, for completeness, data for all patients
except those with large deletions are included in tables 1 and 2. (Some of the data have been published elsewhere, as noted.)
of SHH, GLI3 is cleaved to produce a repressor that
down-regulates target genes. Initial genotype-phenotype
studies led to the hypothesis that GCPS results from
functional haploinsufficiency, a hypothesis that is sup-
ported by the fact that deletions or translocations af-
fecting GLI3 have been described only for individuals
with GCPS (Wagner et al. 1990; Vortkamp et al. 1991)
and not for individuals with PHS. Additionally, point
mutations in the DNA-binding domain were identified
in individuals with GCPS (Kalff-Suske et al. 1999). In
contrast, the first two mutations identified in families
with PHS were truncating mutations just 3′ of the region
that encodes the DNA-binding domain (Kang et al.
1997b). Truncated proteins from these alleles were pre-
dicted to act as constitutive repressors. As the number
of reported mutations in GLI3 increased, the proposed
genotype-phenotype correlation was called into ques-
tion. Indeed, the phrase “GLI3 morphopathies” was
coined to describe the phenotypes caused by GLI3 mu-
tations, because the apparent lack of genotype-pheno-
type correlation precluded phenotypic classification
(Radhakrishna et al. 1999). To resolve this, we analyzed
a large cohort of probands with features of GCPS and/
or PHS. Here, we report the clinical and molecular an-
alyses of 135 patients from 60 families and correlate
the mutations with the clinical manifestations.
Methods
Patients
This study was reviewed and approved by a National
Institutes of Health (NIH) institutional review board
(IRB). The GLI3 project originally included 153 indi-
viduals with PHS or GCPS. Twelve patients with GCPS
were found to have large deletions of GLI3 and have
been reported elsewhere (Johnston et al. 2003). In ad-
dition, six patients with PHS have had both clinical and
mutation results reported elsewhere (Killoran et al. 2000;
Galasso et al. 2001; Turner et al. 2003; Ng et al. 2004);
the remaining 135 subjects (60 probands and 75 affected
relatives) are reported in the present study (fig. 1). Clini-
cal manifestations in individuals from seven families
(PH01, PH02 [Kang et al. 1997a], PH06 [Low et al.
1995], PH17 [Verloes et al. 1995], M19 [Zucchini et al.
1998], GB01 [Baraitser et al. 1983], and GB05 [Ridler
et al. 1977]) have been described elsewhere; two other
probands (from families PH22 [Stroh et al. 1999] and
Johnston et al.: Genotype/Phenotype Analyses in GCPS/PHS 611
PH42 [Haynes and Bagwell 2003]) were the subjects of
case reports after they were enrolled in the present study
but have been included in the “Results” section because
significant additional clinical information was collected.
Four additional families (GB02, GB03, GB04, and GB07)
have been excluded from the “Results” section of the
present study because adequate phenotypic information
about them was not available. The novel clinical data
therefore include 71 patients (49 probands and 22 af-
fected relatives) (individual details given in tables 1 and
2). Of the 49 families, 38 were clinically evaluated at
the NIH. This evaluation included a history, physical
examination, limb radiographs, and cranial imaging. In
accordance with NIH IRB guidelines, young patients
might not have had cranial imaging studies under se-
dation in the absence of clinical indications. Most pa-
tients with PHS were analyzed for bifid epiglottis (On-
drey et al. 2000). Insertional polydactyly is defined as
the presence of a floating metacarpal or metatarsal be-
tween the second and fifth (or most posterior) metacar-
pals or metatarsals or the fusion of metacarpals or meta-
tarsals other than the first or most posterior. Preaxial
polydactyly was evaluated on the basis of whether pha-
langes were fully or partially duplicated. The assessment
of wide or broad thumbs and big toes was a subjective
clinical assessment. The clinical diagnostic criteria for
PHS require the presence of insertional polydactyly and
a hypothalamic hamartoma in the proband (Biesecker
et al. 1996). Family members are considered affected if
they have isolated hamartoma or polydactyly and if they
are a first-degree relative of an affected individual. Spe-
cific clinical diagnostic criteria have not been set for
GCPS (Biesecker 2001); however, suggested criteria in-
clude preaxial polydactyly in at least one limb or ab-
normally wide big toes or thumbs, syndactyly, macro-
cephaly, and hypertelorism. For the present study, we
set relaxed GCPS eligibility criteria of preaxial polydac-
tyly and the presence of at least one additional feature
(syndactyly, macrocephaly, hypertelorism, or postaxial
polydactyly). Family members were considered affected
if they had polydactyly or abnormally wide big toes or
thumbs and were a first-degree relative of an affected
individual. Statistical comparisons were performed by
Fisher’s exact test (InStat), unless otherwise specified.
DNA Isolation
DNA was isolated from whole blood by use of the
salting-out method (Gentra), per the manufacturer’s
instructions.
Sequence Analysis
Sequencing of the GLI3 coding exons was performed
with BigDye terminator cycle sequencing kit v.3 and ei-
ther the ABI 377 or ABI 3100, per the manufacturer’s
protocol (Applied Biosystems Group). Sequence data were
compared with the published GLI3 sequence (GenBank
accession number NM_000168.2; University of Cali-
fornia–Santa Cruz (UCSC) genome assembly, July 2003
freeze) (UCSC Genome Bioinformatics) by use of Se-
quencher 4.12 software.
DHPLC Analysis
For some probands, a screening of exons 3–12 and
the last third of exon 15 was performed using denatur-
ing high-performance liquid chromatography (DHPLC)
(Transgenomic). Primers used for PCR amplification are
shown in table 3, as are gradient temperatures, gradient
durations, and initial starting concentrations of proprie-
tary buffer B (Transgenomic). All gradients were run
using the rapid-gradient option, and the increase in buf-
fer B was 5% per min for all gradients. All amplicons
that produced peak patterns that differed from those of
wild-type controls were sequenced.
Controls for missense variations were also performed
by DHPLC. Controls were run under a single gradient
condition capable of identifying the nucleotide change
of interest (table 4). Eighty ethnically matched control
individuals (160 chromosomes) were analyzed for each
alteration.
qPCR Analysis
Quantitative PCR (qPCR) analysis of the GLI3-cod-
ing exons was performed with Platinum SYBR Green
qPCR SuperMix UDG kit (Invitrogen) and ABI PRISM
7000 (Applied Biosystems Group), per the manufac-
turers’ instructions. Endogenous control amplicons in-
cluded an STS on chromosome 7 and an amplicon from
the deoxynucleotide carrier (DNC) gene on chromosome
17q25.3 (Iacobazzi et al. 2001). A single amplicon from
each coding exon of GLI3 was assayed. Amplification
primers for each GLI3 exon and the controls are listed
in table 5. Copy number was determined using a com-
bination of standard curve and comparative CT method
of analysis.
RT-PCR Analysis
RNA was isolated from lymphoblasts by use of affini-
ty chromatography (RNAeasy and Qiashredders [Qia-
gen]). A combined RT-PCR reaction was performed
using Qiagen’s One Step RT-PCR kit, per the manufac-
turer’s instructions, with the addition of proprietary so-
lution Q. Products were cloned into the TOPO cloning
vector (Invitrogen) and were sequenced using BigDye
terminator cycle sequencing kit v.3 and ABI 377 (Ap-
plied Biosystems Group).
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Table 3
Primer Sets and Amplicon Lengths for Mutation
Detection with DHPLC
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 4
Primer Sets and Amplicon Lengths for Analysis
of Missense Alteration Controls with DHPLC
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Results
This article describes novel data (clinical or molecular
or both) for 135 patients from 60 families, including 20
probands and 26 affected relatives with PHS and 40
probands and 49 affected relatives with GCPS. This in-
cludes novel clinical data for 71 patients and novel mo-
lecular data for 60 probands. Clinical and mutation data
are presented in tables 1 and 2 for patients with PHS
and GCPS, respectively.
Mutation Detection
Causative mutations were identified in 19 probands
with PHS from 20 families and in 28 probands with
GCPS from 40 families. Mutations are listed in tables 1
and 2 and are shown diagrammatically in figure 2B.
Mutation analyses included both sequencing of coding
exons and intron/exon junctions and, when additional
DNA was available, exonic copy-number analysis by use
of qPCR to exclude subgenic deletions in individuals
when sequencing did not reveal alterations.
PHS Mutations
The diagnostic yield for PHS was 95%, since only 1
of 20 individuals who met the PHS diagnostic criteria
did not have an identifiable mutation in GLI3. Muta-
tions in patients with PHS included frameshift and non-
sense mutations in exons 13, 14, and 15 and one splice-
site mutation in intron 14 in one family (PH02). Analyses
of RNA from a hybrid cell line containing this splice
mutation showed production of three splice products.
Sequence analyses of these products showed two splice
products that predict frameshifts at aa 702 and aa 786
(p.T702AfsX14 and p.V786AfsX14, respectively). The
other splice product predicts an in-frame deletion of 75
aa (p.G736_N810del). All mutations identified in pro-
bands with PHS were 3′ of the DNA-binding domain
and predicted the formation of a truncated protein.
GCPS Mutations
Mutations were identified in 28 (70%) of the 40 pro-
bands with GCPS. Alterations in patients with GCPS
included splice-site, frameshift, and nonsense mutations
and exonic deletions and duplications. Sequence analy-
ses revealed 24 causative mutations with only the re-
current p.R792X mutation—identified in three separate
families (G44, GB02, and GB03)—falling within the PHS
mutation area (see the “Discussion” section). This muta-
tion has been reported in three other families with GCPS
(Kalff-Suske et al. 1999; Debeer et al. 2003). Distinct
missense alterations were also identified in 3 (8%) of 40
probands. The first missense alteration, p.C482W in
family G32, affects a conserved cysteine in the C2H2
zinc-finger domain and likely abrogates DNA binding.
The second and third missense alterations, p.R625Q in
family G25 and p.R625W in family G79, affect a highly
conserved arginine in the C2H2 zinc-finger domain;
p.R625W has been reported elsewhere (Debeer et al.
2003). Missense alterations p.C482W and p.R625Q seg-
regated with the disease and were not identified in 160
ethnically matched control chromosomes. Missense al-
teration p.R625W was not present in either parent; pa-
ternity was confirmed.
When a mutation or missense alteration was not de-
tected by sequence analysis and additional DNA was
available, qPCR was performed to detect exonic dele-
tions or duplications. Three deletions and one duplica-
tion were identified among four probands with GCPS.
In patient G19, previous STRP analysis had suggested
that the region surrounding GLI3 on chromosome 7 was
deleted. All STRP markers tested were homozygous/hemi-
zygous in the individual, but parental samples were not
available to confirm a deletion. The qPCR result con-
firmed that the entire GLI3 gene is deleted in the indi-
vidual. In patient G63, qPCR analysis showed a deletion
of exons 3 and 4, and RT-PCR analysis showed exon 2
spliced directly to exon 5, which resulted in a large out-
of-frame deletion (p.E42GfsX58). The qPCR result for
patient G67 predicted a deletion of exon 2. In patient
G46, qPCR predicted a duplication of exons 8–12, a
minimum of 48.8 kb.
Discussion
GLI3 mutations have been associated with several phe-
notypes, including GCPS, PHS, isolated polydactyly, and
acrocallosal syndrome. Initially, large genomic deletions
and translocations were found in patients with GCPS
and led to a mechanistic model of haploinsufficiency
(Wagner et al. 1990; Vortkamp et al. 1991). Subsequently,
point mutations were discovered in individuals with
GCPS (Wild et al. 1997). These could plausibly fit a
haploinsufficiency model, since many were within or up-
stream of the DNA-binding domain and were predicted
to cause loss of function (Wild et al. 1997). In contrast
Figure 2 Type and distribution of GLI3 mutations described for patients with PHS and GCPS. A, Mutation spectrum. No mutations of
the following types have been described for patients with PHS: small in-frame deletions (IFD), translocations (Trans), large deletions (L Del),
exonic deletions or duplications (Exon), and missense mutations (Miss). The correlation of mutation type and phenotype is statistically significant
( [Fisher’s ]) when the classes of mutations were dichotomized into frameshift and nonsense (Trunc) versus all other types andP ! .0001 2# 2
when tested against phenotype (PHS vs. GCPS). B, Diagram of the position within the gene of known nonsense, frameshift, and splice-site
mutations. Some of the closely spaced mutations have been adjusted for increased visual clarity. Splice-site mutations are shown in red. Black
numbers indicate identical mutations, and red numbers indicate multiple mutations in the same splice donor. Data include published mutations
(Bianchi et al. 1981; Tommerup and Nielsen 1983; Marks et al. 1985; Pelz et al. 1986; Wagner et al. 1990; Pettigrew et al. 1991; Vortkamp
et al. 1991; Kang et al. 1997b; Radhakrishna et al. 1997, 1999; Wild et al. 1997; Williams et al. 1997; Kalff-Suske et al. 1999, 2000a, 2000b,
2004; Friez and Stevenson 2000; Killoran et al. 2000; Galasso et al. 2001; Kroisel et al. 2001; Elson et al. 2002; Debeer et al. 2003; Driess et
al. 2003; Freese et al. 2003; Johnston et al. 2003; Kremer et al. 2003; Turner et al. 2003; Ng et al. 2004) and the mutations identified in the
present study. The colored bars on the protein show the conserved domains of GLI3 as defined elsewhere (Ruppert et al. 1990).
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Table 5
Primer Sets and Amplicon Lengths for Mutation
Detection with qPCR
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
to GCPS, mutations reported for individuals with PHS
consistently predicted truncation of the protein C-ter-
minal of the DNA-binding domain. The model was ex-
panded to include a constitutive repressor as the mech-
anism for PHS (Biesecker 1997), which has subsequently
been validated by in vitro experimental data (Wang et
al. 2000) and a mouse model of PHS (Bose et al. 2002).
However, as the GLI3 mutation spectrum grew, it was
suggested that clear genotype-phenotype correlations
were not apparent, and the phrase “GLI3 morphopa-
thies” was proposed (Radhakrishna et al. 1999) to de-
scribe allelic GLI3 phenotypes without clear phenotypic
boundaries. To resolve these two opposing views, we
analyzed additional patients and compiled mutation
data from the literature.
To understand genotype-phenotype correlations, it is
critical to have a clear understanding of the phenotypes.
The diagnostic criteria for PHS require the presence of
(1) a hypothalamic hamartoma and insertional poly-
dactyly in the proband or (2) isolated hamartoma or
polydactyly in a relative of the proband with PHS (Bie-
secker et al. 1996). We analyzed 20 probands (and 26
additional affected relatives) who met the PHS diagnos-
tic criteria. Of those 20 probands, 19 had a mutation 3′
of the GLI3 zinc-finger domain. The spectrum of mu-
tations found in patients with PHS was limited to non-
sense, frameshift, and a single splice mutation (which
generated mostly frameshifted transcripts). The diag-
nostic yield with the use of the PHS clinical criteria is
95% (for finding a mutation of this type in this region
of GLI3). These results are surprisingly robust and sug-
gest that, when the clinical criteria are met, clinical ge-
neticists can rapidly and confidently make a diagnosis
of PHS and can institute appropriate medical care, which
may be life saving (Biesecker 2003). Mutation analysis
is supportive and useful for many reasons but is not
necessary for initiation of this care.
In contrast to the situation for PHS, defined diag-
nostic criteria do not yet exist for GCPS. This is not
surprising, since GCPS comprises relatively few features,
which are relatively nonspecific and are found in nu-
merous other disorders. For example, preaxial poly-
dactyly is recognized as a manifestation of at least 25
syndromes (Stevenson et al. 1993), and hypertelorism
is recognized as a symptom of at least 68 syndromes
(Jones 1997). The situation for PHS is very different;
hypothalamic hamartoma is recognized as a symptom
of only four syndromes and insertional polydactyly of
only six. It is important to emphasize that the clinical
diagnostic challenge for GCPS is to distinguish it from
disorders other than PHS, since PHS and GCPS are
readily distinguished from each other. The suggested
diagnostic criteria for GCPS include preaxial polydac-
tyly in at least one limb or abnormally wide big toes or
thumbs, syndactyly, macrocephaly, and hypertelorism.
For the present study, we set relaxed GCPS eligibility
criteria of preaxial polydactyly and the presence of at
least one additional feature (syndactyly, macrocephaly,
hypertelorism, or postaxial polydactyly).
The cohort described here (with the use of the relaxed
criteria) included 89 patients (40 probands and 49 af-
fected relatives) with GCPS. Of the five individuals who
fulfilled the strict diagnostic criteria for GCPS, all five
(100%) of the individuals had mutations in GLI3. In
the complete cohort of 40 probands, mutations were
identified in a total of 28 (70%), and additional mis-
sense alterations were revealed in 3 (8%). Although the
diagnostic yield for mutation detection in patients who
fulfilled the strict GCPS clinical criteria was 100%, the
difference in the two diagnostic yields was not statis-
tically significant. In addition, the relaxed clinical cri-
teria allowed many more cases to be screened, so the
absolute yield was higher. An intriguing observation is
that hypertelorism is uncommon among the relaxed-
criteria group who were not found to have a mutation
in GLI3. Further study of this subgroup is necessary to
determine the clinical and biological significance of this
apparent finding.
We conclude that many patients who present with
features in the GCPS spectrum may not have manifes-
tations amenable to phenotypic diagnosis because of
variable severity and the nonspecific clinical features of
GCPS. The presentation of a patient with some (but not
all) features of GCPS may require clinicians to have a
high level of clinical suspicion and to follow up with
molecular diagnostics. We suggest that these relaxed
clinical criteria would be most useful in selecting pa-
tients for molecular analysis instead of in making a clini-
cal diagnosis in the absence of molecular data. Fortu-
nately, GCPS is not associated with life-threatening
complications (as is PHS), so withholding diagnosis un-
til molecular confirmation can be made is an appropri-
ate strategy.
The spectrum of GLI3 mutations in patients with
GCPS is large, and there are no efficient algorithms to
detect all of these mutations. We have suggested (John-
ston et al. 2003) that patients with suspected GCPS
should have a standard giemsa-banded karyotype (to
exclude the presence of translocations). If the result is
normal, it should be followed by GLI3 FISH. If the
FISH results are also normal, it should be followed by
GLI3-mutation scanning by use of sequence analysis
and, if necessary, qPCR or another method for detection
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of exonic copy number. Further research is necessary to
make this algorithm more sensitive and less expensive,
since it would currently cost at least U.S. $3,000 for
these four tests (Johnston et al. 2003).
When the mutation data from the existing literature
(Bianchi et al. 1981; Tommerup and Nielsen 1983;
Marks et al. 1985; Pelz et al. 1986; Wagner et al. 1990;
Pettigrew et al. 1991; Vortkamp et al. 1991; Wild et al.
1997; Williams et al. 1997; Kalff-Suske et al. 1999,
2000a, 2000b, 2004; Radhakrishna et al. 1999; Friez
and Stevenson 2000; Killoran et al. 2000; Galasso et
al. 2001; Kroisel et al. 2001; Elson et al. 2002; Debeer
et al. 2003; Driess et al. 2003; Freese et al. 2003; John-
ston et al. 2003; Kremer et al. 2003; Turner et al. 2003;
Ng et al. 2004) and the present study are compiled, a
clear genotype-phenotype correlation emerges. We ap-
proached the question of genotype-phenotype correla-
tion on two levels: first, attempting to correlate distinct
types of mutations with the phenotypes and, second,
correlating the positions of mutations within the gene
for the classes of mutations (frameshift, nonsense, and
splicing) that are present in both disorders. When all
mutation types are included, a correlation is demon-
strated. Patients with GCPS have translocations, large
deletions (i.e., detectable by FISH assay with BAC
probes), exonic deletions and duplications, small in-
frame deletions, and missense, splicing, frameshift, and
nonsense mutations (a total of 92 mutations [fig. 2A]).
In striking contrast, only nonsense, frameshift, and a
single splice-site mutation were found in 32 patients
with PHS. To test for significance, we dichotomized mu-
tation types into two groups, truncating and nontrun-
cating; these two groups were significantly ( )P ! .0001
correlated with phenotype (PHS and GCPS). We con-
clude that these data refute prior assertions of a lack of
correlation of GLI3 genotype and phenotype (Radha-
krishna et al. 1999).
However, additional insights can be gained by analy-
sis of the classes of mutations—frameshift, nonsense,
and splicing—that are shared by both phenotypes. We
and others (Kalff-Suske et al. 1999) have shown that
mutations 3′ of the zinc-finger domain are present in
patients with GCPS, and it was unclear how these mu-
tations differed from those identified in patients with
PHS. When all frameshift, nonsense, and splicing mu-
tations are combined, mutations causing GCPS and PHS
fall in distinct regions of GLI3 (fig. 2B). PHS is typically
caused by mutations in the middle third of the gene,
whereas GCPS is caused by mutations outside that re-
gion. Although we had previously hypothesized (Bie-
secker 1997) that all frameshift or nonsense mutations
3′ of the DNA-binding domain would cause PHS or
PAP-A, it is now clear that there are patients with mu-
tations in the far 3′ end of the gene and that all of them
have GCPS. There are several potential mechanisms that
could explain a GCPS phenotype with these mutations.
The presence of a truncated protein C-terminal of aa
1161 may make the protein subject to ubiquitination
or other modes of protein degradation, the protein may
be mislocalized to an organelle or other subcellular
structure that leads to loss of function, or these trun-
cations may trigger nonsense-mediated mRNA decay.
This will be difficult to test, because GLI3 is present at
very low levels in adult cells and because it is technically
challenging to engineer numerous mutations into model
organisms (i.e., mouse) to test these hypotheses.
The genotype-phenotype correlation is not perfect.
Intriguingly, there are now six independent families (in-
cluding three families reported here) with GCPS and the
p.R792X nonsense mutation, which is in the PHS mu-
tation region. The three families with the p.R792X mu-
tation reported here clearly had GCPS, and the brief
clinical data from the prior reports of patients with the
p.R792X mutation suggest that they most likely have
GCPS as well (Kalff-Suske et al. 1999; Debeer et al.
2003). This causation of GCPS by this mutation is dif-
ficult to explain, but the mutation may generate a pro-
tein that is targeted for degradation or an mRNA that
is subjected to nonsense-mediated mRNA decay. Prelimi-
nary data argue against mRNA decay, since the mutant
and wild-type message levels appear similar in a lym-
phoblast line from a patient with p.R792X (from family
G44) (data not shown). Two other mutations, p.R667X
and p.L1146RfsX95, overlap known PHS mutations.
The p.R667X mutation is adjacent to the 5′ border of
the PHS domain (aa 666), and p.L1146RfsX95 predicts
a protein that is highly charged at the carboxyl end,
which may affect its function. Additional research is
needed to determine if these mutations conflict with or
correspond to our model of GLI3 pathogenesis. The
splice-site mutation found in family PH02 with PHS is
interesting, since the data reported here suggest that
the mutation is consistent with our model. This splice-
site mutation generates several cDNA products, includ-
ing an in-frame product with a 75-aa deletion (pre-
dicting p.G736_N810del) and two products that predict
frameshifts at aa 702 and aa 786 (p.T702AfsX14 and
p.V786AfsX14). We conclude that this mutant allele
generates only a portion of the transcripts that are re-
pressors (since two of three sequenced splice variants
have frameshifts) and a portion of transcripts with an
in-frame deletion. This is consistent with the phenotype
in this family (a large family with mild PHS) and with
the model of truncated repressor alleles causing PHS.
The PHS and GCPS phenotypes breed true and cor-
relate strongly with mutation type and position. A GLI3
deletion, translocation, small in-frame deletion, exonic
deletion/duplication, or missense mutation causes GCPS
(as found in 37 patients with GCPS and no patients with
PHS). A GLI3 nonsense, frameshift, or splice-site mu-
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tation causes GCPS if it occurs 5′ of nt 1998 or 3′ of nt
3481 (as found in 47 patients with GCPS and no pa-
tients with PHS) and is correlated with PHS if it occurs
between those nucleotides (as found in 8 patients with
GCPS and 32 patients with PHS). The data show a clear
correlation of genotype and phenotype on two levels
(mutation type with phenotype and mutation position
with phenotype for truncating mutations). The data re-
fute prior assertions of a lack of correlation and show
how these data can be useful in clinical practice and
in refining our models of the physiology and patho-
physiology of GLI3 action.
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